Butyric Acid

Butyric Acid

SCHEMBL50507

CCCC(=O)O.OCCO

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.81
HDAC3 O15379 1/20 0.81
HDAC1 Q13547 1/20 0.81
HDAC2 Q92769 1/20 0.81
HDAC8 Q9BY41 1/20 0.81
AKR1B1 P15121 1/20 0.52
GPR84 Q9NQS5 8/20 0.50
PPARG P37231 7/20 0.50
PPARD Q03181 7/20 0.50
PPARA Q07869 7/20 0.50
HDAC11 Q96DB2 5/20 0.50
TSHR P16473 4/20 0.50
PTPN1 P18031 3/20 0.50
ALDH1A1 P00352 2/20 0.50
TLR2 O60603 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
FABP4 P15090 2/20 0.50
FFAR1 O14842 2/20 0.50
FFAR4 Q5NUL3 2/20 0.50
SLC22A6 Q4U2R8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL3281949 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL273910 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL1515937 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL28265205 0.97 FFAR3 (0.77) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL27826311 0.97 FFAR3 (0.77) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL31032327 0.94 FFAR3 (0.72) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL29707585 0.94 FFAR3 (0.72) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL181441 0.94 FFAR3 (0.72) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL181423 0.94 FFAR3 (0.72) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL14698052 0.94 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 494 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113980252-B Continuous production method of modified poly (butylene succinate) 上海师范大学 2023-09-01 CN claimed
CN-113980252-A Continuous production method of modified poly (butylene succinate) 上海师范大学 2022-01-28 CN claimed
CN-113527765-A Polylactic acid composition and additive composition thereof, plastic product and preparation method thereof 浙江兴越材料技术有限公司 2021-10-22 CN claimed
CN-111892874-A Double decomposition unsaturated polyol ester primer and preparation method thereof 安徽江锐新材料有限公司 2020-11-06 CN claimed
CN-101914299-A Flame retardant, flame-retarded resin compositions, and process for production of the flame retardant SONY CORP 2010-12-15 CN claimed
CN-101851399-A Halogen-free flame retardant polyester product and preparation method thereof SHANDONG XINGQIANG TECHNOLOGY CO LTD 2010-10-06 CN claimed
US-7781506-B2 Poly(vinyl alcohol) composition comprising a polyol E.I. DU PONT DE NEMOURS AND COMPANY (US) 2010-08-24 US claimed
US-20080182937-A1 Poly(vinyl alcohol) composition comprising polyol KURARAY CO., LTD. (JP) 2008-07-31 US claimed
CN-1957037-A Flame retardant, flame-retardant resin composition and method for producing the flame retardant SONY CORP (JP) 2007-05-02 CN claimed
EP-3076946-B1 COMPOSITIONS COMPRISING ANTIOXIDANT, FLUID DISPENSERS, AND METHODS INVOLVING THE SAME ALZET LLC (US) 2026-01-07 EP disclosed
EP-4633581-A1 A TOPICAL COMPOSITION Rock & Herb Pte Ltd (SG) 2025-10-22 EP disclosed
EP-4549055-A1 INK COMPOSITION Daicel Corporation (JP) 2025-05-07 EP disclosed
US-20250127776-A1 ORAL PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-04-24 US disclosed
US-20250057835-A1 ORAL PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-02-20 US disclosed
US-4021311-A Recovery of alkylene glycols by azeotropic distillation with 1,2,3-trimethyl benzene HALCON INTERNATIONAL, INC. (US) 1977-05-03 US disclosed
US-4008719-A Osmotic system having laminar arrangement for programming delivery of active agent ALZA CORPORATION (US) 1977-02-22 US disclosed
US-3997613-A PLASTICIZER REICHHOLD CHEMICALS, INC. (US) 1976-12-14 US disclosed
US-3997614-A ANTIOXIDANT REICHHOLD CHEMICALS, INC. (US) 1976-12-14 US disclosed
US-3968174-A MULTISTAGE HALCON INTERNATIONAL, INC. (US) 1976-07-06 US disclosed
US-3968175-A ALKENEDIOLS FROM THE DIOL MONOESTER, MULTISTAGE HALCON INTERNATIONAL, INC. (US) 1976-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250127776-A1 ORAL PHARMACEUTICAL COMPOSITION LIPA, CYP2C19, PNLIP FFAR3 1639/4885HDAC3 2674/4885HDAC1 2213/4885
US-20250057835-A1 ORAL PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND CYP2C19, CYP2C18, CYP3A7 FFAR3 2306/4885HDAC3 500/4885HDAC1 468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.